breast cancer, AstraZeneca and chemotherapy

US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Science Daily9h
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Medscape1d
Drugmakers Are Limiting Cancer Patients’ Access to Financial Lifelines. Why?
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
Hosted on MSN1d
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
AdventHealth in Palm Coast adds advanced cancer treatment center to its Flagler campus
The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...
Targeted Oncology9h
Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
The American Journal of Managed Care2d
Breast Cancer Stage May Influence Risk of Prevalent CVD
Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.
LIVE
KVRR13h
LIVE: Better Testing Coverage for Breast Cancer Patients
The American Cancer Society is asking North Dakota State lawmakers to pass legislation that would require insurance companies to cover diagnostic testing for people who need it when doctors find ...